StockData

Burning Rock Biotech vs NeoGenomics

BNR and NEO side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BNR and NEO compare

NeoGenomics grew revenue faster over the last twelve months (11.1% versus 4.6% for Burning Rock Biotech).

NeoGenomics keeps more of each dollar of sales as profit, with a net margin of −4.1% compared with −10.3% at Burning Rock Biotech.

NeoGenomics scores higher on the StockData Score (11 against 4 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBNRNEO
Size and price
Market cap–$2.0B
Share price$12.74$15.41
Change, 1 year12.5%53.9%
Change, 5 years−90.8%−58.0%
Beta (5Y)2.500.84
Employees6672,500
StockData Score
Total score411 (better)
Valuation score03 (better)
Growth score14 (better)
Performance score13 (better)
Health score2 (better)1
Dividend score00
Valuation
P/S–2.5×
P/B–2.5×
FCF yield–−1.4%
Fair value–$19.92
Margin of safety–22.6%
Growth
Revenue growth (TTM)4.6%11.1% (better)
Revenue growth, 5Y average4.6%10.4% (better)
Profitability
Gross margin74.7% (better)44.8%
Operating margin−10.2%−6.3% (better)
Net margin−10.3%−4.1% (better)
FCF margin−6.2%−3.6% (better)
Return on equity−9.9%−3.9% (better)
Return on invested capital−72.5%−4.6% (better)
Financial health
Debt / equity0.00 (better)0.47
Interest coverage–−15.2×
Current ratio2.993.53 (better)
Altman Z-score–2.32
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield–−0.02%
Shareholder yield–−0.02%
Ownership
Held by institutions1.8%112%
Held by insiders19.0%1.5%
Insider net buying, 12 months$11.6M (better)−$717K
Short interest, % of float–10.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.